Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial

OBJECTIVE: Burosumab, an anti-fibroblast growth factor 23 antibody, was recently approved for the treatment of X-linked hypophosphatemia (XLH). We evaluated the safety and efficacy of burosumab in pediatric XLH patients. METHODS: This open-label, phase 3/4 trial of ≤ 124 weeks’ duration was conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Namba, Noriyuki, Kubota, Takuo, Muroya, Koji, Tanaka, Hiroyuki, Kanematsu, Masanori, Kojima, Masahiro, Orihara, Shunichiro, Kanda, Hironori, Seino, Yoshiki, Ozono, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962727/
https://www.ncbi.nlm.nih.gov/pubmed/35356008
http://dx.doi.org/10.1210/jendso/bvac021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962727/
https://www.ncbi.nlm.nih.gov/pubmed/35356008
http://dx.doi.org/10.1210/jendso/bvac021

Ejemplares similares